Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2017/0267782 PROTEIN ASSAY METHOD SPECIFIC TO TRACP-5b (TARTRATE RESISTANT ACID PHOSPHATASE 5b)
The purpose of the present invention is to provide a monoclonal antibody that is useful in specifically assaying tartrate resistant acid phosphatase 5b...
2017/0267781 Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the...
2017/0267780 MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES
The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased)...
2017/0267779 DOSAGE AND ADMINISTRATION OF ANTI-EGFR THERAPEUTICS
Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating...
2017/0267778 HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES
Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a...
2017/0267777 SACCHARIDE-BASED BIOMARKERS AND THERAPEUTICS
Provided are antibodies that specifically bind to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine expressed by a cancer cell or an...
2017/0267776 RSPO3 Binding Agents and Uses Thereof
The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer....
2017/0267775 CD27L Antigen Binding Proteins
The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody...
2017/0267774 SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs),...
2017/0267773 ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred...
2017/0267772 SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES
The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological...
2017/0267771 AGONISTIC ANTIBODY TO CD27
The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which...
2017/0267770 Methods for Detecting 1,25-Dihydroxyvitamin D and Related Antibodies
There is disclosed an assay method for selectively detecting 1,25-dihydroxy-vitamin D in a biological fluid sample. According to the method, the pH of the test...
2017/0267769 ST2 ANTIGEN BINDING PROTEINS
Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the...
2017/0267768 Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof
Provided by the present disclosure are antibodies (e.g., scFvs) that include CDRs and human framework regions that confer useful properties upon the...
2017/0267767 BIOMARKER PROFILES FOR PREDICTING OUTCOMES OF CANCER THERAPY WITH ERBB3 INHIBITORS AND/OR CHEMOTHERAPIES
Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer...
2017/0267766 IGF-1R ANTIBODY AND ITS USE AS ADDRESSING VEHICLE FOR THE TREATMENT OF CANCER
The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid...
2017/0267765 ANTI-EGFR ANTIBODY AND USES OF SAME
This disclosure relates generally to an EGFR antibody and its therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with...
2017/0267764 ANTI-MICA ANTIBODIES
The present invention provides antigen-binding proteins capable of binding to human MICA polypeptides. The antigen-binding proteins have increased activity in...
2017/0267763 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is...
2017/0267762 ANTI PD-1 ANTIBODIES
The present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-1, and to methods of using such antibodies and ...
2017/0267761 Agents, Uses and Methods for Treatment
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In...
2017/0267760 Checkpoint Blockade and Microsatellite Instability
Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer....
2017/0267759 ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAGS as well as...
2017/0267758 IMMUNOTHERAPY WITH BINDING AGENTS
Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also...
2017/0267757 COMPOSITION FOR PREVENTING OR TREATING LUNG CANCER COMPRISING ANTIBODY AGAINST CD66C AND CHEMOTHERAPEUTIC AGENT
A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a...
2017/0267756 TAGGED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF
The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the...
2017/0267755 ISOLATED ANTI-MESOTHELIN ANTIBODIES, CONJUGATES AND USES THEREOF
Embodiments in accordance with the present disclosure include antibody binding domains that specifically bind to mesothelin. A nanobody or conjugate construct...
2017/0267754 ANTI-TLR4 ANTIBODIES AND USES THEREOF
This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as...
2017/0267753 COMBINATION THERAPY FOR CO-ADMINISTRATION OF MONOCLONAL ANTIBODIES
Disclosed are methods for enhancing the efficacy of monoclonal antibody therapy, which entails co-administering a therapeutic monoclonal antibody, or a...
2017/0267752 TNF BINDERS
The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha ("TNF" or "TNF-alpha"). In particular,...
2017/0267751 PROLONGATION OF SURVIVAL OF AN ALLOGRAFT BY INHIBITING COMPLEMENT ACTIVITY
Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant...
2017/0267750 Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain and Mucin...
The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and...
2017/0267749 ENDOTROPHIN NEUTRALIZATION AND USE THEREOF
Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of...
2017/0267748 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE
Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids...
2017/0267747 Protein Therapeutant And Method For Treating Cancer
The present invention relates to compositions for treating cancer by having one or more activities of inhibiting cancer growth, inhibiting cancer cell...
2017/0267746 TECHNIQUES OF PREPARING COLLAGEN ACTIVE PEPTIDES
A method of preparing collagen active peptides with antiproliferative activity against cancer cells. The collagen active peptides are obtained by hydrolysis of...
2017/0267745 FACTOR VIII GLYCOFORMS
The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides...
2017/0267744 Systems for Factor VIII Processing and Methods Thereof
The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a...
2017/0267743 FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients...
2017/0267742 TRANSGENE GENETIC TAGS AND METHODS OF USE
The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and...
2017/0267741 TUMOR VASCULAR DISRUPTING AGENT POLYPEPTIDE, GENE, EXPRESSION VECTOR, AND USE THEREOF
The present invention relates to a tumor vascular disrupting agent polypeptide, gene, expression vector, and use thereof. The tumor vascular disrupting agent...
2017/0267740 PEPTIDES ASSOCIATED WITH HLA-DR MHC CLASS II MOLECULE AND INVOLVED IN RHEUMATOID ARTHRITIS
Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are...
2017/0267739 CHIMERIC ANTIGEN RECEPTORS TO CONTROL HIV INFECTION
The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise...
2017/0267738 TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing...
2017/0267737 Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
The present invention relates to glypican-3-specific T-cell receptors. The present invention further relates to soluble TCR constructs, chimeric TCRs,...
2017/0267736 IGF-I POLY (ETHYLENE GLYCOL) CONJUGATES
Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an...
2017/0267735 VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS
The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding...
2017/0267734 NOVEL PROTEINS SPECIFIC FOR PYOVERDINE AND PYOCHELIN
The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical...
2017/0267733 Novel Read-Through Fusion Polynucleotides and Polypeptides and Uses Thereof
The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.